MatriSys Bioscience is pioneering the development of biopharmaceuticals that utilize beneficial bacteria sourced from healthy human skin to address chronic inflammatory skin conditions such as atopic dermatitis, acne, and Netherton syndrome. Their innovative Skin Microbiome Discovery Platform identifies and optimizes these beneficial bacteria, which play a crucial role in maintaining skin health by protecting against pathogens and supporting immune functions. The company’s approach aims to restore skin homeostasis disrupted by dysbiosis, a condition where the balance of the skin microbiome is altered, leading to exacerbated symptoms of various skin diseases.

The lead clinical program, MSB-0221, specifically targets atopic dermatitis, a prevalent condition affecting millions. Current treatments often involve steroids and immunosuppressants, which can have adverse effects. In contrast, MatriSys's bacteriotherapy seeks to correct the microbial ecosystem of the skin, thereby reducing the overgrowth of harmful bacteria like Staphylococcus aureus. By reintroducing beneficial strains, the therapy aims to enhance the skin's natural defenses, improve barrier function, and alleviate inflammation, offering a novel and potentially safer alternative for patients suffering from chronic skin conditions.

United States

MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. 
 


MatriSys Bioscience

Company Details